Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Status:
Completed
Trial end date:
2017-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether apremilast is safe and effective in the
treatment of patients with psoriatic arthritis who have not been previously treated with
DMARDs.
Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and
swollen joints, pain, physical function) in treated patients.